<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC6961902/table_1" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 1</label>
  <title>Characteristics of the included trials.</title>
 </caption>
 <colgroup span="1">
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
  <col align="left" valign="middle" span="1"/>
 </colgroup>
 <thead>
  <tr>
   <th align="left" rowspan="1" colspan="1" id="0-0-.">Study</th>
   <th align="left" rowspan="1" colspan="1" id="0-1-.">Year</th>
   <th align="left" rowspan="1" colspan="1" id="0-2-.">Region</th>
   <th align="justify" rowspan="1" colspan="1" id="0-3-.">Study design</th>
   <th align="justify" rowspan="1" colspan="1" id="0-4-.">Mean age (y)</th>
   <th align="justify" rowspan="1" colspan="1" id="0-5-.">Sex</th>
   <th align="justify" rowspan="1" colspan="1" id="0-6-.">Intervention</th>
   <th align="justify" rowspan="1" colspan="1" id="0-7-.">Control</th>
   <th align="justify" rowspan="1" colspan="1" id="0-8-.">Duration</th>
   <th align="justify" rowspan="1" colspan="1" id="0-9-.">Follow-up</th>
   <th align="justify" rowspan="1" colspan="1" id="0-10-.">Dropo 
    <br/>ut 
   </th>
   <th align="justify" rowspan="1" colspan="1" id="0-11-.">Outcomes</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="left" rowspan="1" colspan="1">Sun et al[ 
    <a rid="pone.0227532.ref017" ref-type="bibr">17</a>] 
   </td>
   <td align="left" rowspan="1" colspan="1">2017</td>
   <td align="left" rowspan="1" colspan="1">Shanghai</td>
   <td align="left" rowspan="1" colspan="1">CCT</td>
   <td align="left" rowspan="1" colspan="1">42.8±13.2</td>
   <td align="left" rowspan="1" colspan="1">M:28 F:10</td>
   <td align="left" rowspan="1" colspan="1">LAM (100 mg/day 
    <br/>orally)+ACEI/ARB (n = 20) 
   </td>
   <td align="left" rowspan="1" colspan="1">ACEI/ARB alone (n = 18)</td>
   <td align="left" rowspan="1" colspan="1">12 mo</td>
   <td align="left" rowspan="1" colspan="1">12 mo</td>
   <td align="left" rowspan="1" colspan="1">0</td>
   <td align="left" rowspan="1" colspan="1">①②</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Bhimma et al[ 
    <a rid="pone.0227532.ref018" ref-type="bibr">18</a>] 
   </td>
   <td align="left" rowspan="1" colspan="1">2002</td>
   <td align="left" rowspan="1" colspan="1">Durban, South Africa</td>
   <td align="left" rowspan="1" colspan="1">CCT</td>
   <td align="left" rowspan="1" colspan="1">8.9</td>
   <td align="left" rowspan="1" colspan="1">M:34 F:5</td>
   <td align="left" rowspan="1" colspan="1">IFN-α2b (10 million units/m2 3 times/week)(n = 19)</td>
   <td align="left" rowspan="1" colspan="1">control of edema and hypertension (n = 20)</td>
   <td align="left" rowspan="1" colspan="1">16 weeks</td>
   <td align="left" rowspan="1" colspan="1">40 weeks</td>
   <td align="left" rowspan="1" colspan="1">5</td>
   <td align="left" rowspan="1" colspan="1">①②③</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Tang et al[ 
    <a rid="pone.0227532.ref019" ref-type="bibr">19</a>] 
   </td>
   <td align="left" rowspan="1" colspan="1">2005</td>
   <td align="left" rowspan="1" colspan="1">Hong Kong, China</td>
   <td align="left" rowspan="1" colspan="1">CCT</td>
   <td align="left" rowspan="1" colspan="1">45.5±19.0</td>
   <td align="left" rowspan="1" colspan="1">M:14 F:8</td>
   <td align="left" rowspan="1" colspan="1">LAM 100mg/d+ACEI or ARB (n = 10)</td>
   <td align="left" rowspan="1" colspan="1">ACEI/ARB (n = 12)</td>
   <td align="left" rowspan="1" colspan="1">NA</td>
   <td align="left" rowspan="1" colspan="1">49.2±16.5 mo</td>
   <td align="left" rowspan="1" colspan="1">0</td>
   <td align="left" rowspan="1" colspan="1">①③</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Panomsak et al[ 
    <a rid="pone.0227532.ref020" ref-type="bibr">20</a>] 
   </td>
   <td align="left" rowspan="1" colspan="1">2006</td>
   <td align="left" rowspan="1" colspan="1">Thailand</td>
   <td align="left" rowspan="1" colspan="1">CCT</td>
   <td align="left" rowspan="1" colspan="1">40.9</td>
   <td align="left" rowspan="1" colspan="1">M:10 F:7</td>
   <td align="left" rowspan="1" colspan="1">1 month of prednisone, then 6 had LAM and 1 had IFN-α (n = 7)</td>
   <td align="left" rowspan="1" colspan="1">ACEI, fish oil, or neither (n = 10)</td>
   <td align="left" rowspan="1" colspan="1">NA</td>
   <td align="left" rowspan="1" colspan="1">5–120 mo</td>
   <td align="left" rowspan="1" colspan="1">3</td>
   <td align="left" rowspan="1" colspan="1">①</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Sun et al[ 
    <a rid="pone.0227532.ref021" ref-type="bibr">21</a>] 
   </td>
   <td align="left" rowspan="1" colspan="1">2012</td>
   <td align="left" rowspan="1" colspan="1">Seoul, Korea</td>
   <td align="left" rowspan="1" colspan="1">CCT</td>
   <td align="left" rowspan="1" colspan="1">37</td>
   <td align="left" rowspan="1" colspan="1">M:9 F:1</td>
   <td align="left" rowspan="1" colspan="1">Antiviral drugs (n = 6)</td>
   <td align="left" rowspan="1" colspan="1">ACEI or ARB (n = 4)</td>
   <td align="left" rowspan="1" colspan="1">NA</td>
   <td align="left" rowspan="1" colspan="1">mean 87 mo (8–187)</td>
   <td align="left" rowspan="1" colspan="1">1</td>
   <td align="left" rowspan="1" colspan="1">①</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Lai et al[ 
    <a rid="pone.0227532.ref022" ref-type="bibr">22</a>] 
   </td>
   <td align="left" rowspan="1" colspan="1">1991</td>
   <td align="left" rowspan="1" colspan="1">Hong Kong, China</td>
   <td align="left" rowspan="1" colspan="1">CCT</td>
   <td align="left" rowspan="1" colspan="1">30</td>
   <td align="left" rowspan="1" colspan="1">M:14 F:2</td>
   <td align="left" rowspan="1" colspan="1">IFN-α2b (3 million units, 3 times/week, subcutaneous injection)(n = 5)</td>
   <td align="left" rowspan="1" colspan="1">diuretic agents/dipyridamole /no treatment (n = 11)</td>
   <td align="left" rowspan="1" colspan="1">12 weeks</td>
   <td align="left" rowspan="1" colspan="1">55.1 mo</td>
   <td align="left" rowspan="1" colspan="1">0</td>
   <td align="left" rowspan="1" colspan="1">①②③</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Lin et al[ 
    <a rid="pone.0227532.ref023" ref-type="bibr">23</a>] 
   </td>
   <td align="left" rowspan="1" colspan="1">1995</td>
   <td align="left" rowspan="1" colspan="1">Taiwan, China</td>
   <td align="left" rowspan="1" colspan="1">RCT</td>
   <td align="left" rowspan="1" colspan="1">6.5±3.3</td>
   <td align="left" rowspan="1" colspan="1">M:29 F:11</td>
   <td align="left" rowspan="1" colspan="1">IFN-α2b (5μ if body weight&lt;20 kg, 8μ if body weight&gt;20 kg, 3 times/week subcutaneous injection)</td>
   <td align="left" rowspan="1" colspan="1">control 
    <br/>of edema and hypertension 
   </td>
   <td align="left" rowspan="1" colspan="1">12 mo</td>
   <td align="left" rowspan="1" colspan="1">24 mo</td>
   <td align="left" rowspan="1" colspan="1">0</td>
   <td align="left" rowspan="1" colspan="1">③</td>
  </tr>
 </tbody>
 <tfoot>
  <p class="fn" charset="fn" id="t001fn001">
   <p>Abbreviations: RCT, randomized controlled trial; CCT, cohort clinical trial; M, male; F, female; LAM, lamivudine; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; NA, not available; mo, months; ①Renal remission; ②eGFR (estimated glomerular filtration rate); ③HBeAg clearance.</p>
  </p>
 </tfoot>
</table>
